The DOI matches its Crossref record.
Drugs and Steatohepatitis
Abstract
In addition to the usual associations with insulin resistance, type 2 diabetes, central obesity, and hypertriglyceridemia, nonalcoholic steatohepatitis (NASH) has been associated with several drugs and toxins. However, drug-induced liver disease is a relatively uncommon cause of steatohepatitis. The term drug-induced steatohepatitis is preferred when the association appears to result from a direct toxic effect of the drug on the liver. For some agents implicated as causing cirrhosis or fatty liver disorders, the association may be coincidental because NASH is a common component of the insulin resistance (or metabolic) syndrome. In other instances, corticosteroids, tamoxifen, and estrogens may precipitate NASH in predisposed persons by exacerbating insulin resistance, central obesity, diabetes, and hypertriglyceridemia, and methotrexate may worsen hepatic fibrosis in NASH. Drug-induced steatohepatitis is associated with prolonged therapy (more than 6 months) and possibly drug accumulation, which in the case of perhexiline maleate is favored by a genetic polymorphism of CYP2D6 that leads to slow perhexiline oxidation. The toxic mechanism appears to involve mitochondrial injury, which causes steatosis because of impaired beta-oxidation of fatty acids, and leads to generation of reactive oxygen species and ATP depletion. Thus, drug-induced steatohepatitis may provide clues to injurious events in the more common metabolic forms of NASH. A clinical feature of some types of drug-induced steatohepatitis is progression after discontinuation of the causative agent. It follows that early recognition of hepatotoxicity is crucial to prevent the development of severer forms of liver disease and improve the clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Watterson, K. R., Bestow, D., Gallagher, J., Hamilton, D. L., Ashford, F. B., Meakin, P. J., & Ashford, M. L. J. (2013) · Neurosignals · doi:10.1159/000334144 · Cited by 3,389
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis
Rolo, A. P., Teodoro, J. S., & Palmeira, C. M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.10.003 · Cited by 955
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Begriche, K., Massart, J., Robin, M.-A., Borgne-Sanchez, A., & Fromenty, B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.11.006 · Cited by 555
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Younossi, Z. M., Rinella, M. E., Sanyal, A. J., Harrison, S. A., Brunt, E. M., Goodman, Z., Cohen, D. E., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.31420 · Cited by 417
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Unalp, A., Behling, C. E., Lavine, J. E., & Neuschwander‐Tetri, B. A. (2009) · Hepatology · doi:10.1002/hep.22724 · Cited by 390
Steatosis: Co-factor in Other Liver Diseases *
Powell, E. E., Jonsson, J. R., & Clouston, A. D. (2005) · Hepatology · doi:10.1002/hep.20750 · Cited by 374
Watanabe, S., Hashimoto, E., Ikejima, K., Uto, H., Ono, M., Sumida, Y., Seike, M., Takei, Y., Takehara, T., Tokushige, K., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1050-7 · Cited by 327
Labbe, G., Pessayre, D., & Fromenty, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00608.x · Cited by 317
The ins and outs of mitochondrial dysfunction in NASH
Fromenty, B., Robin, M., Igoudjil, A., Mansouri, A., & Pessayre, D. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70098-8 · Cited by 266
KIRSCH, R., CLARKSON, V., SHEPHARD, E. G., MARAIS, D. A., JAFFER, M. A., WOODBURNE, V. E., KIRSCH, R. E., & HALL, P. D. L. M. (2003) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2003.03198.x · Cited by 262
Rosenberg, P., Urwitz, H., Johannesson, A., Ros, A.-M., Lindholm, J., Kinnman, N., & Hultcrantz, R. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.01.024 · Cited by 185
Mitochondria: the gateway for tamoxifen-induced liver injury
Ribeiro, M. P. C., Santos, A. E., & Custódio, J. B. A. (2014) · Toxicology · doi:10.1016/j.tox.2014.05.009 · Cited by 70
“Some patients also develop hepatic fibrosis, cirrhosis and hepatic necrosis (Oien et al., 1999; Storen et al., 2000; Farrell, 2002).”
Background
Metadata
- Authors
- Farrell, G.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002-05-16
- Volume
- 22
- Issue
- 02
- Pages
- 185-194
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W1981018347
- Cited by
- 231
- References
- 0
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.